Premium
Histone deacetylase inhibitor sodium butyrate promotes the osteogenic differentiation of rat adipose‐derived stem cells
Author(s) -
Hu Xiaoqing,
Fu Yutuo,
Zhang Xin,
Dai Linghui,
Zhu Jingxian,
Bi Zhenggang,
Ao Yingfang,
Zhou Chunyan
Publication year - 2014
Publication title -
development, growth and differentiation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 66
eISSN - 1440-169X
pISSN - 0012-1592
DOI - 10.1111/dgd.12119
Subject(s) - sodium butyrate , runx2 , adipose tissue , stem cell , microbiology and biotechnology , histone deacetylase , histone deacetylase inhibitor , epigenetics , mesenchymal stem cell , biology , chemistry , histone , transcription factor , cell culture , endocrinology , biochemistry , genetics , gene
Adult stem cells hold great promise for use in tissue repair and regeneration. Recently, adipose tissue‐derived stem cells ( ADSC s) were found to be an appealing alternative to bone marrow stem cells ( BMSC s) for bone tissue engineering. The main benefit of ADSC s is that they can be easily and abundantly available from adipose tissue. However, our prior study discovered an important phenomenon that BMSC s have greater osteogenic potential than ADSC s in vitro and epigenetic regulation plays a critical role in runt‐related transcription factor 2 (Runx2) expression and thus osteogenesis. In this study, we aimed to improve the osteogenic potential of ADSC s by histone deacetylase inhibitor sodium butyrate (NaBu). We found that NaBu promoted rat ADSC osteogenic differentiation by altering the epigenetic modifications on the Runx2 promoter.